Subject: CIIX to Present at NIBA in New York and Yibao Biologics' Annual Conference

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube will continue to sell CBD health products through online retailing methods to the world's nearly 1.4 billion Chinese people.
Hot Stock to WatchHot Stock to Watch

Company:, Inc. (OTCQB: CIIX)


Price: 1.12

Change (%): - 0.11 (8.94)

Volume: 183,161
CIIX Chart, Inc. to Present at the National Investment Banking Association Conference in New York City on February 28, 2017

NEW YORK, February 28, 2017 /PRNewswire/ - (OTCQB: CIIX) (the “Company”), the premier financial information website for Chinese-speaking investors in both the U.S. and China, today announced its management team will be presenting at the National Investment Banking Association Conference in New York City on February 28, 2017. The conference location is at the Westin New York Grand Central Hotel on 42nd Street and 3rd Avenue in Midtown Manhattan. The Company presents in the morning on February 28th.

The Company will also be presenting alongside the team from WallStreet Research™, who is sponsoring, Inc. at the event. WallStreet Research™ recently updated its Corporate Profile research report on the company. WallStreet Research™ has also organized selected one-on-one meetings for the company at the Penn Club of New York.

Continue Reading Presents at Yibao Biologics' Annual Conference, Optimistic About Direct Selling Opportunity in China

NEW YORK, Feb. 27, 2017 /PRNewswire/ - (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces that company CEO Warren Wang attended Shangdong Yibao Biologics Co. Ltd.’s annual conference, and, by invitation, delivered a five-minute speech to celebrate the 18th anniversary of Yibao Biologics.

Yibao Biologics is a modern high-tech enterprise which specializes in the research, production and sales of chondroitin sulfate series and Confucian series health care products. The company is also the largest and most professional manufacturer of chondroitin sulfate in the world. Yibao Biologics invited to participate in its annual direct sales conference to discuss the development and prospects of Chinese health products enterprises in the United States.

As an attendee of the conference, Wang learned how direct sales of the health products industry operate in China, and how to apply this information to build the sales team of CIIX’s retail website. He also delivered a five-minute speech at the conference and received continuous applause from more than 5,000 direct sales persons in attendance.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks